Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

New-onset Atrial Fibrillation Predicts Heart Failure Progression

Bleeding Toes in Diabetic Neuropathy

No evidence that AF type significantly impacts stroke risk

Grip Strength Predicts Cause-Specific Mortality in Middle-Aged and Elderly Persons Hideo Sasaki, MD, PhD, Fumiyoshi Kasagi, PhD, Michiko Yamada, MD, PhD,

Circ Cardiovasc Qual Outcomes

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

Role of the CHADS2 Score in Acute Coronary Syndromes

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

CHADS2 Score Predicts Postoperative Atrial Fibrillation in Patients Undergoing Elective Pulmonary Lobectomy Svetlana Kotova, MD, Mansen Wang, PhD, Katie.

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Laurent Macle, MD, John Cairns, MD, Kori.

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation Lena Rivard, MD, MSc, Paul Khairy, MD,

Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II Menno V. Huisman,

Characteristics of Hospitalized Patients with Atrial Fibrillation in Taiwan: A Nationwide Observation Cheng-Han Lee, MD, Ping-Yen Liu, MD, PhD, Liang-Miin.

Volume 137, Issue 2, Pages (February 2010)

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Bleeding Toes in Diabetic Neuropathy

Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study Lars Frost, MD, PhD, Lone Juul Hune,

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

‘Real-World’ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey Gregory Y.H. Lip, MD, Cécile Laroche, MSc, Gheorghe-Andrei Dan,

Epidemiology of Myelodysplastic Syndromes

Long-Term Risk of Ischemic Stroke After the Cox-Maze III Procedure for Atrial Fibrillation Anders Albåge, MD, PhD, Ulrik Sartipy, MD, PhD, Göran Kennebäck,

The Impact of Race on the Prognosis of Preclinical Diastolic Dysfunction: A Large Multiracial Urban Population Study Jian Shan, MD, Lili Zhang, MD, MSc,

Intentional Brodifacoum Ingestion

Cardiovascular Disease and CKD: Core Curriculum 2010

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

Antithrombotic Therapy for Atrial Fibrillation

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

TIA for the Internist The American Journal of Medicine

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Gout in African Americans

The New Lipid Guidelines: What Do Primary Care Clinicians Think?

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease: Data from the Nord-Trøndelag Health Study Trine Moholdt,

When Guidelines Cause Hypertension

Left atrial appendage exclusion: An alternative to anticoagulation in nonvalvular atrial fibrillation Kareem Bedeir, MBChB, MS, David R. Holmes, MD,

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Molly E. Waring, PhD, Jane S

Optimizing Atrial Fibrillation Management

The Malnourished Heart: An Unusual Case of Heart Failure

Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study Walid Saliba, MD, MPH, Naomi.

Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study Anna Gu, MD, PhD, Yu Yue,

Eroded Pacemaker in an Elderly Patient

To Reduce Stroke with PFO Closure, Respect the Shunt

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

Purple Urinary Bag Syndrome

The American Journal of Medicine

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Erratum Canadian Journal of Cardiology

Higher Cardiovascular Disease Prevalence and Mortality among Younger Blacks Compared to Whites Stacey Jolly, MD, MS, Eric Vittinghoff, PhD, Arpita Chattopadhyay,

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Falls in Older Adults: Risk Assessment, Management and Prevention

Figure 8. Stroke prevention strategy in patients with AF

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

Jay S. Kaufman, PhD, Sam Harper, PhD The American Journal of Medicine

Hypophosphatemia: Diagnostic Significance in Legionnaires’ Disease

Presentation transcript:

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip, MD, Robby Nieuwlaat, PhD, Ron Pisters, PhD, Harry J.G.M. Crijns, MD, Alfonso Iorio, MD The American Journal of Medicine Volume 127, Issue 10, Pages 979-986.e2 (October 2014) DOI: 10.1016/j.amjmed.2014.05.003 Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 1 Cardioembolic and bleeding risk scores co-distribution. A, CHADS2 and HAS-BLED scores. B, CHADS2 and HAS-BLED risk categories. C, CHA2DS2-VASc and HAS-BLED scores. D, CHA2DS2-VASc and HAS-BLED risk categories. Red line: median of HAS-BLED scores. CHADS2 = Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack, Vascular disease, Age 65-75, Sex category i.e. females; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly. The American Journal of Medicine 2014 127, 979-986.e2DOI: (10.1016/j.amjmed.2014.05.003) Copyright © 2014 Elsevier Inc. Terms and Conditions

Supplementary Figure 1 Cardioembolic and bleeding risk scores co-distribution according to antithrombotic therapy prescribed at discharge. (A) CHADS2 and HAS-BLED. (B) CHA2DS2-VASc and HAS-BLED. Median of HAS-BLED scores (red line). AP = antiplatelet agent; CHADS2 = Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack, Vascular disease, Age 65-75, Sex category i.e. females; HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly; No = no therapy; VKA = vitamin K antagonist. The American Journal of Medicine 2014 127, 979-986.e2DOI: (10.1016/j.amjmed.2014.05.003) Copyright © 2014 Elsevier Inc. Terms and Conditions